ArticleAntimicrobial agents and chemotherapy2003
Susceptibilities of simian immunodeficiency virus to protease inhibitors.
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Enhanced antiretroviral therapy in rhesus macaques improves RT-SHIV viral decay kinetics.Antimicrobial agents and chemotherapy · 2014Article
- Can humanized mice reflect the complex pathobiology of HIV-associated neurocognitive disorders?Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2012Review
- Simian immunodeficiency virus macaque models of HIV latency.Current opinion in HIV and AIDS · 2011Review
- Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS.PloS one · 2010Article
- Synergistic effect of human CycT1 and CRM1 on HIV-1 propagation in rat T cells and macrophages.Retrovirology · 2009Article
- Simian immunodeficiency virus SIVagm dynamics in African green monkeys.Journal of virology · 2008Article
- Direct inactivation of human immunodeficiency virus type 1 by a novel small-molecule entry inhibitor, DCM205.Antimicrobial agents and chemotherapy · 2007Article
- HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
- Ring substituent effects on biological activity of vinyl sulfones as inhibitors of HIV-1.Bioorganic & medicinal chemistry · 2007Article
- Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.Journal of virology · 2005Article
- Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.Antimicrobial agents and chemotherapy · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We used a focal infectivity assay with HeLa H1-JC.37 cells to directly compare susceptibilities of simian immunodeficiency virus (SIV) and human immunodeficiency virus type 1 (HIV-1) to protease inhibitors. SIVmac239 was inhibited by indinavir, saquinavir, and ritonavir, with 50% effective concentrations (means +/- standard deviations) of 39 +/- 8, 55 +/- 3, and 13 +/- 5 nM, respectively. The corresponding values for inhibition of HIV-1 were 66 +/- 4, 47 +/- 10, and 25 +/- 14 nM, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.